ZDHHC3 and neoplasm: Blockade of PD-L1 palmitoylation with 2BP, siRNA knockdown of zDHHC3 or a competitive, cell-penetrating disruptor peptide that prevented palmitoylation of PD-L1 by zDHHC3 promoted anti-tumor immunity in vitro and inhibited tumor growth in vivo, providing a new strategy for targeting PD-L1-dependent tumor immune escape (185).